Risks and Benefits of Antiplatelet Therapy in Uremic Patients

被引：12
|
作者：
Washam, Jeffrey B.
Adams, George L. [1 ]
机构：
[1] Duke Univ, Med Ctr, Dept Med, Duke Heart Ctr, Durham, NC 27710 USA
来源：
ADVANCES IN CHRONIC KIDNEY DISEASE | 2008年 / 15卷 / 04期
关键词：
Uremia; Antiplatelet therapy; Acute coronary syndrome;
D O I：
10.1053/j.ackd.2008.07.006
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Patients with renal insufficiency are at an increased risk for cardiovascular morbidity and mortality. Despite being at a substantial risk for thrombotic events, patients with renal insufficiency also experience a greater number of hemorrhagic complications associated with antiplatelet therapy than individuals with normal renal function. This review focuses on the benefits and risks of antiplatelet therapy in patients with impaired kidney function suffering from an acute coronary syndrome. (C) 2008 by the National Kidney Foundation, Inc. All rights reserved
引用
收藏
页码：370 / 377
页数：8
相关论文
共 50 条
  • [1] Resumption of antiplatelet therapy in patients with primary intracranial haemorrhage: Balancing benefits and risks
    Khan, Ahsan A.
    Lip, Gregory Y. H.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2018, 384 : 139 - 140
  • [2] Combined antiplatelet and anticoagulant therapy: clinical benefits and risks
    Eikelboom, J. W.
    Hirsh, J.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 : 255 - 263
  • [3] Combining Antiplatelet and Antithrombotic Therapy (Triple Therapy): What Are the Risks and Benefits?
    Asencio, Luis Alejandro
    Huang, Jennifer J.
    Alpert, Joseph S.
    [J]. AMERICAN JOURNAL OF MEDICINE, 2014, 127 (07): : 579 - 585
  • [4] Anticoagulant and antiplatelet therapy in patients with chronic kidney disease: risks versus benefits review
    Harmon, John P.
    Zimmerman, Danielle L.
    Zimmerman, Deborah L.
    [J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2013, 22 (06): : 624 - 628
  • [5] Benefits and risks with antiplatelet therapy: how great a problem is bleeding?
    Husted, Steen
    [J]. EUROPEAN HEART JOURNAL SUPPLEMENTS, 2008, 10 (0I) : 19 - 24
  • [6] Benefits and risks of continued dual antiplatelet therapy after coronary stenting
    不详
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 (03) : 200 - 200
  • [7] Patient and Physician Perspectives on the Benefits and Risks of Antiplatelet Therapy for Acute Coronary Syndrome
    Cohen, Marc
    Jones, Colin
    [J]. CARDIOLOGY AND THERAPY, 2024, 13 (03) : 631 - 643
  • [8] Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction
    Yeh, Robert W.
    Kereiakes, Dean J.
    Steg, Philippe Gabriel
    Windecker, Stephan
    Rinaldi, Michael J.
    Gershlick, Anthony H.
    Cutlip, Donald E.
    Cohen, David J.
    Tanguay, Jean-Francois
    Jacobs, Alice
    Wiviott, Stephen D.
    Massaro, Joseph M.
    Iancu, Adrian C.
    Mauri, Laura
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (20) : 2211 - 2221
  • [9] Patients Perception of Risks and Benefits of Biologic Therapy
    De Felice, Kara Mari
    [J]. INFLAMMATORY BOWEL DISEASES, 2020, 26 (01) : 147 - 149
  • [10] Balancing the Risks and Benefits of Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery
    Rao, Sunil, V
    Ohman, E. Magnus
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (06): : 532 - 533
12345